[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-study-detail:100601023":3},{"organization":4,"outcomesModule":7,"designInfo":16,"detailedDescription":11,"studyPopulation":11,"armGroups":27,"interventions":40,"overallOfficials":48,"centralContacts":52,"locations":58,"responsibleParty":193,"collaborators":11,"id":195,"slug":11,"hasResults":196,"nctId":197,"briefTitle":198,"officialTitle":199,"acronym":11,"eligibilityCriteria":200,"healthyVolunteers":196,"sex":201,"minAge":202,"maxAge":203,"enrollmentInfo":204,"targetDuration":11,"studyType":207,"phases":208,"briefSummary":210,"conditions":211,"keywords":11,"overallStatus":61,"whyStopped":11,"lastUpdateSubmitDate":213,"lastUpdatePostDateStruct":214,"startDateStruct":217,"completionDateStruct":219,"leadSponsor":221,"locationsCount":222},{"fullName":5,"class":6},"Neurocrine Biosciences","INDUSTRY",{"primaryOutcomes":8,"secondaryOutcomes":13,"otherOutcomes":11},[9],{"measure":10,"description":11,"timeFrame":12},"Change From Baseline in Positive and Negative Syndrome Scale (PANSS) Total Score at Week 5",null,"Baseline, Week 5",[14],{"measure":15,"description":11,"timeFrame":12},"Change From Baseline in Clinical Global Impression - Severity (CGI-S) Score at Week 5",{"allocation":17,"interventionModel":18,"interventionModelDescription":11,"primaryPurpose":19,"observationalModel":11,"timePerspective":11,"maskingInfo":20},"RANDOMIZED","PARALLEL","TREATMENT",{"masking":21,"maskingDescription":11,"whoMasked":22},"QUADRUPLE",[23,24,25,26],"PARTICIPANT","CARE_PROVIDER","INVESTIGATOR","OUTCOMES_ASSESSOR",[28,34],{"label":29,"type":30,"description":31,"interventionNames":32},"NBI-1117568","EXPERIMENTAL","Participants will receive NBI-1117568 once daily (QD) orally from Day 1 to Day 35 for a total of 5 weeks.",[33],"Drug: NBI-1117568",{"label":35,"type":36,"description":37,"interventionNames":38},"Placebo","PLACEBO_COMPARATOR","Participants will receive matching placebo QD orally from Day 1 to Day 35 for a total of 5 weeks.",[39],"Drug: Placebo",[41,45],{"type":42,"name":29,"description":43,"armGroupLabels":44,"otherNames":11},"DRUG","NBI-1117568 will be administered per schedule specified in the arm description.",[29],{"type":42,"name":35,"description":46,"armGroupLabels":47,"otherNames":11},"Placebo will be administered per schedule specified in the arm description.",[35],[49],{"name":50,"affiliation":5,"role":51},"Clinical Development Lead","STUDY_DIRECTOR",[53],{"name":54,"role":55,"phone":56,"phoneExt":11,"email":57},"Neurocrine Medical Information Call Center","CONTACT","877-641-3461","medinfo@neurocrine.com",[59,73,81,89,98,107,117,126,134,144,154,159,167,177,185],{"facility":60,"status":61,"city":62,"state":63,"zip":64,"country":65,"countryCode":66,"cosmosGeoPoint":67,"geoPoint":72,"contacts":11},"Neurocrine Clinical Site","RECRUITING","Culver City","California","90230","United States","US",{"type":68,"coordinates":69},"Point",[70,71],-118.39647,34.02112,{"lat":71,"lon":70},{"facility":60,"status":61,"city":74,"state":63,"zip":75,"country":65,"countryCode":66,"cosmosGeoPoint":76,"geoPoint":80,"contacts":11},"Garden Grove","92845",{"type":68,"coordinates":77},[78,79],-117.94145,33.77391,{"lat":79,"lon":78},{"facility":60,"status":61,"city":82,"state":63,"zip":83,"country":65,"countryCode":66,"cosmosGeoPoint":84,"geoPoint":88,"contacts":11},"Riverside","92506",{"type":68,"coordinates":85},[86,87],-117.39616,33.95335,{"lat":87,"lon":86},{"facility":60,"status":61,"city":90,"state":91,"zip":92,"country":65,"countryCode":66,"cosmosGeoPoint":93,"geoPoint":97,"contacts":11},"Atlanta","Georgia","30328",{"type":68,"coordinates":94},[95,96],-84.38798,33.749,{"lat":96,"lon":95},{"facility":60,"status":61,"city":99,"state":100,"zip":101,"country":65,"countryCode":66,"cosmosGeoPoint":102,"geoPoint":106,"contacts":11},"North Canton","Ohio","44720",{"type":68,"coordinates":103},[104,105],-81.40234,40.87589,{"lat":105,"lon":104},{"facility":60,"status":61,"city":108,"state":11,"zip":109,"country":110,"countryCode":111,"cosmosGeoPoint":112,"geoPoint":116,"contacts":11},"Sliven","8800","Bulgaria","BG",{"type":68,"coordinates":113},[114,115],26.32558,42.68607,{"lat":115,"lon":114},{"facility":60,"status":118,"city":119,"state":11,"zip":120,"country":110,"countryCode":111,"cosmosGeoPoint":121,"geoPoint":125,"contacts":11},"WITHDRAWN","Veliko Tarnovo","5047",{"type":68,"coordinates":122},[123,124],25.62904,43.08124,{"lat":124,"lon":123},{"facility":60,"status":61,"city":127,"state":11,"zip":128,"country":110,"countryCode":111,"cosmosGeoPoint":129,"geoPoint":133,"contacts":11},"Vratsa","3001",{"type":68,"coordinates":130},[131,132],23.56312,43.21052,{"lat":132,"lon":131},{"facility":60,"status":61,"city":135,"state":11,"zip":136,"country":137,"countryCode":138,"cosmosGeoPoint":139,"geoPoint":143,"contacts":11},"Győr","9024","Hungary","HU",{"type":68,"coordinates":140},[141,142],17.63512,47.68333,{"lat":142,"lon":141},{"facility":60,"status":61,"city":145,"state":11,"zip":146,"country":147,"countryCode":148,"cosmosGeoPoint":149,"geoPoint":153,"contacts":11},"Brasov","500123","Romania","RO",{"type":68,"coordinates":150},[151,152],25.60613,45.64861,{"lat":152,"lon":151},{"facility":60,"status":61,"city":145,"state":11,"zip":155,"country":147,"countryCode":148,"cosmosGeoPoint":156,"geoPoint":158,"contacts":11},"507190",{"type":68,"coordinates":157},[151,152],{"lat":152,"lon":151},{"facility":60,"status":61,"city":160,"state":11,"zip":161,"country":147,"countryCode":148,"cosmosGeoPoint":162,"geoPoint":166,"contacts":11},"Bucharest","41914",{"type":68,"coordinates":163},[164,165],26.10626,44.43225,{"lat":165,"lon":164},{"facility":60,"status":61,"city":168,"state":11,"zip":169,"country":170,"countryCode":171,"cosmosGeoPoint":172,"geoPoint":176,"contacts":11},"Belgrade","11000","Serbia","RS",{"type":68,"coordinates":173},[174,175],20.46513,44.80401,{"lat":175,"lon":174},{"facility":60,"status":61,"city":178,"state":11,"zip":179,"country":170,"countryCode":171,"cosmosGeoPoint":180,"geoPoint":184,"contacts":11},"Gornja Toponica","18202",{"type":68,"coordinates":181},[182,183],21.46075,43.21417,{"lat":183,"lon":182},{"facility":60,"status":61,"city":186,"state":11,"zip":187,"country":170,"countryCode":171,"cosmosGeoPoint":188,"geoPoint":192,"contacts":11},"Kragujevac","34000",{"type":68,"coordinates":189},[190,191],20.91667,44.01667,{"lat":191,"lon":190},{"type":194,"investigatorFullName":11,"investigatorTitle":11,"investigatorAffiliation":11,"oldNameTitle":11,"oldOrganization":11},"SPONSOR","100601023",false,"NCT07105098","NBI-1117568-SCZ3030: Evaluation of NBI-1117568 in Inpatient Adults With Schizophrenia","A Global, Phase 3, Multicenter, Randomized, Double-Blind, Placebo-Controlled Study to Assess the Efficacy, Safety, and Tolerability of NBI-1117568 in Adults With Schizophrenia Who Warrant Inpatient Hospitalization","Key Inclusion Criteria:\n\n* Participant has a primary diagnosis of schizophrenia\n* Participant is experiencing an acute exacerbation or relapse of symptoms and currently warrants hospitalization.\n* Participants taking prohibited medications, including antipsychotics, must discontinue before study participation\n* Participant is willing and able to remain in an inpatient setting for the study duration, follow instructions, and comply with the protocol requirements\n\nKey Exclusion Criteria:\n\n* Participant has known hypersensitivity to any component of the formulation of NBI-1117568\n* Participant has an unstable or poorly controlled medical condition or chronic disease\n* Participant is considered by the investigator to be at imminent risk of suicide or injury to self or others\n* Participant has a diagnosis of moderate or severe substance use disorder (with the exception of nicotine or caffeine dependence) within 6 months prior to screening\n* Participant has a positive alcohol test or drug screen for disallowed substances\n* Participant has a history of poor or suspected poor compliance in clinical research studies and\u002For in the investigator's opinion, the participant is not capable of adhering to the protocol requirements.\n\nNote: Other protocol-specified inclusion\u002Fexclusion criteria may apply.","ALL","18 Years","65 Years",{"count":205,"type":206},284,"ESTIMATED","INTERVENTIONAL",[209],"PHASE3","The primary objective for this study is to evaluate the efficacy of NBI-1117568 compared with placebo on improving behavioral and psychological symptoms of schizophrenia in adults.",[212],"Schizophrenia","2026-05-13",{"date":215,"type":216},"2026-05-15","ACTUAL",{"date":218,"type":216},"2025-08-11",{"date":220,"type":206},"2027-11",{"name":5,"class":6},15]